Evidence map›Paper›PMID 37391843›Full record

ArticleLipids in health and disease2023

Adipose tissue dysfunction serum markers are associated with high density lipoprotein size and glycation in the early stages of type 2 diabetes.

Esteban Jorge-Galarza, Aida Medina-Urrutia, Juan Reyes-Barrera, Margarita Torres-Tamayo, Luis Felipe Montaño-Estrada, Araceli Páez-Arenas, Felipe Massó-Rojas, Juan Gabriel Juárez-Rojas

Open access · goldAbstract read
In one paragraph

Article in Lipids in health and disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Effect of Diet on HDL in Obesity.Molecules (Basel, Switzerland) · 2024
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Esteban Jorge-GalarzaDepartamento de Endocrinología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
Aida Medina-UrrutiaDepartamento de Endocrinología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
Juan Reyes-BarreraDepartamento de Endocrinología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
Margarita Torres-TamayoDepartamento de Endocrinología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
Luis Felipe Montaño-EstradaLaboratorio de Inmunobiología, Departamento de Biología Celular y Tisular, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico.
Araceli Páez-ArenasLaboratorio de Medicina Traslacional, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
Felipe Massó-RojasLaboratorio de Medicina Traslacional, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
Juan Gabriel Juárez-RojasDepartamento de Endocrinología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico. gaboyk2@gmail.com.
Instituto Nacional de Cardiología · MXUniversidad Nacional Autónoma de México · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHigh-density lipoproteins (HDLs) have antiatherogenic properties related to their chemical structure. Adipose tissue (AT) influences HDL reverse cholesterol transport and plasma HDL cholesterol levels. However, whether AT dysfunction affects HDL subpopulations and their glycation in early type 2 diabetes (T2D) is still unknown.

objectiveTo investigate the association of inflammation and AT dysfunction serum markers with the size and glycation of HDLs in normoglycemic, prediabetes, and T2D subjects.

methodsWe assessed HDL particle size and advanced glycation end-product (AGE) content in HDLs isolated from normoglycemic (n = 17), prediabetes (n = 17), and recently T2D-diagnosed (n = 18) subjects. Insulin, adiponectin, and plasminogen activator inhibitor 1 (PAI-1) were determined using the Bio-Rad Multiplex Platform, and free fatty acids (FFAs) and high sensitivity C-reactive protein (hs-CRP) were determined by standard procedures. The AT insulin resistance (ATIR) index and ATIR/adiponectin and adiponectin/leptin ratios were calculated.

resultsHDL was progressively smaller (nm) and enriched with AGE (mg-BSA-AGE/mg protein) according to the glucose categories: 8.49 and 7.5 in normoglycemic subjects, 8.44 and 12.4 in prediabetic subjects, and 8.32 and 14.3 in T2D subjects (P = 0.033 and P = 0.009 for size and AGE, respectively). In multivariable regression analysis, the ATIR/adiponectin ratio was inversely associated with HDL size (β = -0.257, P = 0.046), and the ATIR ratio was directly associated with HDL glycation (β = 0.387, P = 0.036). In contrast, adiponectin and the adiponectin/leptin ratio were not associated with alterations in HDL particles. Furthermore, HDL size was associated with resistin (β = -0.348, P = 0.007) and PAI-1 (β = -0.324, P = 0.004). HDL and AGE were related to insulin concentrations (β = 0.458, P = 0.015). Analyses were adjusted for age, sex, body mass index, triglycerides, and HDL-cholesterol.

conclusionHDL size was significantly associated with the ATIR/adiponectin ratio and inflammation, whereas glycation was more strongly related to the ATIR index. These findings have important implications for the management and prevention of cardiovascular disease in T2D patients.

Indexed as

Diabetes Mellitus, Type 2Prediabetic StateAdiponectinAdipose TissueBiomarkersCholesterol, HDLGlycation End Products, AdvancedHumansInsulinLeptinLipoproteins, HDLMaillard ReactionPlasminogen Activator Inhibitor 1AdiponectinBiomarkersCholesterol, HDLGlycation End Products, AdvancedInsulinLeptinLipoproteins, HDLPlasminogen Activator Inhibitor 1Adipose tissue dysfunctionAdvanced glycation end productsAnd high-density lipoprotein sizeHigh-density lipoproteinsType 2 diabetes

Identifiers

PMID37391843
PMCPMC10314544
OpenAlexW4382651756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.